Big Board

Content Ideas
Result Content Idea Research
Result Content Idea Research
1 Severe acute respiratory syndrome‐coronavirus‐2 spike (S) protein based vaccine candidates: State of the art and future prospects
2 Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients
3 Molecular simulations reveal detailed structure and dynamics of SARS-CoV-2 spike protein
4 ACROBiosystems and the Fight Against COVID-19
5 De novo design of picomolar SARS-CoV-2 miniprotein inhibitors
6 Looking for hidden states of the COVID-19 spike protein
7 Antibody-like proteins that capture and neutralize SARS-CoV-2
8 Researchers use molecular dynamics simulations to identify secrets of SARS-CoV-2 virus
9 Leaving no stone unturned: Allosteric targeting of SARS-CoV-2 Spike protein at putative druggable sites disrupts human angiotensin-converting enzyme interactions at the receptor binding domain
10 Beckman Coulter Completes First In A Series Of Antibody Neutralization Studies
11 Advanced model reveals dynamic motions of SARS-COV-2 spike-shielding glycans
12 Human bivalent SARS-CoV-2 neutralizing antibodies more potent
13 D614G mutation in SARS-CoV-2 increases viral fitness and infectivity
14 Accelerated Screen Identifies 25 Existing Drugs Capable of Disrupting SARS-CoV-2 Cell Entry
15 S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit
16 A Comprehensive Toolkit for SARS-CoV-2 Research | Lab Equipment
17 The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients
18 Distinct conformational states of SARS-CoV-2 spike protein
19 Assessing the SARS-CoV-2 threat to wildlife: Potential risk to a broad range of mammals
20 Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
21 COVID-19 Vaccine May Not Need to Achieve Highest Possible RBD-S Antibody Levels, Say Researchers
22 Structural impact on SARS-CoV-2 spike protein by D614G substitution
23 A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
24 Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2
25 Cell entry mechanisms of SARS-CoV-2
26 D614G mutation alters SARS-CoV-2 spike conformational dynamics and protease cleavage susceptibility at the S1/S2 junction
27 Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2
28 Identifying pathophysiological bases of disease in COVID-19
29 Newly developed fusion protein could improve COVID-19 research
30 Dyadic C1 protein expression platform explored in fight against COVID-19
31 Vaccines likely to be effective against SARS-CoV-2 D614G mutation
32 Viral infection and smell loss: The case of COVID‐19
33 The Origin of Sars-Cov-2 As Determined by Scientists
34 Dyadic Updates Market on COVID-19 Initiatives
35 SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines
36 What is a Receptor-Binding Domain (RBD)?
37 SureClinical Supports Accelagen COVID-19 Phase 2 Trial with Complimentary Access to SureClinical Platform
38 Infectivity of SARS-CoV-2 with Spike Protein Mutations
39 Protective antibodies persist for months in survivors of serious COVID-19 infections: Study also demonstrates that measuring antibodies can be an accurate tool for tracking the spread of the virus in the community
40 Computer-aided drug design against spike glycoprotein of SARS-CoV-2 to aid COVID-19 treatment
41 Army Researchers Collaborate on Universal Antibody Test for COVID-19
42 Immune Responses Long-Lasting After Serious COVID-19
43 Genomic and proteomic mutation landscapes of SARS‐CoV‐2
44 Sanofi Translate Bio MRT5500 COVID-19 vaccine shows promise in preclinical trials
45 Site-specific glycan analysis of the SARS-CoV-2 spike
46 Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model
47 COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
48 Prevalence of SARS-CoV-2 with D614G mutation in a second wave infection in Houston
49 Future developments in biosensors for field‐ready SARS‐CoV‐2 virus diagnostics
50 Neutralizing SARS-CoV-2 via S protein
51 A closer look at Canada's homegrown COVID-19 vaccine candidates
52 Innate immunity during SARS‐CoV‐2: evasion strategies and activation trigger hypoxia and vascular damage
53 The receptor binding domain of the SARS-CoV-2
54 SARS-CoV-2 spike protein hidden as pH changes
55 Structure-based design of prefusion-stabilized SARS-CoV-2 spikes
56 An entire trimeric S-protein of SARS-CoV-2 is necessary for protective immune response
57 Study reveals how essential SARS-CoV-2 protein can be stabilized and scaled for production
58 Serology study provides critical insight into COVID-19 immune response
59 Structures and distributions of SARS-CoV-2 spike proteins on intact virions
60 Structural Characterization of N‐Linked Glycans in the Receptor Binding Domain of the SARS‐CoV‐2 Spike Protein and their Interactions with Human Lectins
61 Texas Biomed with the University of Alabama at Birmingham and Aridis Pharmaceuticals develop a neutralizing human monoclonal antibody against SARS-CoV-2
62 Could Glycans Hold the Key to Attacking Coronavirus at its Source?
63 ProterixBio announces commercial availability of a semi-quantitative COVID-19 antibody test
64 Researchers stabilize the closed SARS-CoV-2 spike trimer
65 Potential roles of medicinal plants for the treatment of viral diseases focusing on COVID‐19: A review
66 Scientists demonstrate how COVID-19 infects human cells
67 A cost-effective scalable production of SARS-CoV-2 RBD in yeast
68 Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody
69 COVID-19 Antibody Testing: S vs. N Protein
70 Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins
71 Human neutralizing antibodies elicited by SARS-CoV-2 infection
72 Structure-based drug designing and immunoinformatics approach for SARS-CoV-2
73 Inhibition of coronavirus spike protein binding to ACE2
74 Spike protein and human ACE2 binding ability shows SARS-CoV-2 viral adaptation
75 Avidity of binding responsible for cross-neutralization of SARS-CoV-1 and SARS-CoV-2
76 Inhaled antibody treatment for COVID-19 shows pre-clincial success
77 Striking CryoEM image of SARS-CoV-2
78 Emergence of SARS-CoV-2 through recombination and strong purifying selection
79 Study shows engineered SARS-CoV-2 spike protein may be utilized for vaccine development
80 Structural basis of a shared antibody response to SARS-CoV-2
81 Picomolar inhibitors to SARS-CoV-2 proteins
82 New method to rapidly evaluate virus-neutralizing antibodies
83 N terminal domain of S protein revealed as antibody target for COVID-19
84 Detection of SARS-CoV-2 N-Protein Binding Antibodies May Not Correlate With Presence of Neutralizing Antibodies
85 Epygen Biotech partners with Dyadic International for COVID-19 vaccine development
86 Researchers produce first fully-glycosylated full-length SARS-CoV-2 spike protein models
87 Scientists Produce First Open Source All-Atom Models of COVID-19 'Spike' Protein
88 Experts discuss promising strategies for tackling SARS-CoV-2
89 A perspective on potential antibody-dependent enhancement of SARS-CoV-2
90 SARS-CoV-2 receptor ‘mimic' could prevent COVID-19
91 Convergent antibody responses to SARS-CoV-2 in convalescent individuals
92 Assay to Detect Antibodies to SARS-CoV-2 in Human Serum or Plasma
93 De novo designed SARS-CoV-2 nanoparticle vaccine
94 Research progress and challenges to coronavirus vaccine development
95 A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures
96 Scientists Produce 3D Map of SARS-CoV-2's Spike Protein | Medicine
97 War of sugars
98 Possible SARS-CoV-2 Vulnerability Revealed by Human Antibody
99 Finding Camel-ot: A Holy Grail against pandemic SARS-CoV-2?
100 Coronaviruses do not readily induce cross-protective antibody responses